Kontafarma China Holdings Limited (HKG:1312)
0.0340
+0.0010 (3.03%)
Sep 18, 2026, 3:59 PM HKT
Kontafarma China Holdings Revenue
Kontafarma China Holdings had revenue of 383.35M HKD in the half year ending June 30, 2026, a decrease of -16.39%. This brings the company's revenue in the last twelve months to 845.33M, down -5.20% year-over-year. In the year 2025, Kontafarma China Holdings had annual revenue of 914.71M with 1.92% growth.
Revenue (ttm)
845.33M
Revenue Growth
-5.20%
P/S Ratio
0.22
Revenue / Employee
1.35M
Employees
625
Market Cap
190.01M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 914.71M | 17.19M | 1.92% |
| Dec 31, 2024 | 897.52M | 88.41M | 10.93% |
| Dec 31, 2023 | 809.11M | -84.96M | -9.50% |
| Dec 31, 2022 | 894.06M | 90.80M | 11.30% |
| Dec 31, 2021 | 803.27M | -205.87M | -20.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zhongzhi Pharmaceutical Holdings | 1.90B |
| Lee's Pharmaceutical Holdings | 1.54B |
| Shenzhen Neptunus Interlong Bio-technique Company | 1.05B |
| Wai Yuen Tong Medicine Holdings | 683.44M |
| Qianhai Health Holdings | 453.03M |
| Tianda Pharmaceuticals | 350.53M |
| PuraPharm Corporation | 323.49M |
| Fusen Pharmaceutical Company | 318.79M |